Stay updated with breaking news from Ivir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) gapped down before the market opened on Thursday . The stock had previously closed at $26.67, but opened at $25.67. Vir Biotechnology shares last traded at $25.89, with a volume of 100,878 shares trading hands. Analyst Ratings Changes VIR has been the topic of several research analyst reports. […]
Biopharmaceutical company Atea Pharmaceuticals, Inc. (AVIR) announced Tuesday that its Board of Directors unanimously rejected the unsolicited proposal from Tang Capital Partners, LP on behalf of Concentra Biosciences, LLC to acquire all outstanding common shares of Atea for $5.
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) major shareholder Endurance (Cayman) Ltd Svf sold 104,384 shares of the firm’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $26.15, for a total transaction of $2,729,641.60. Following the completion of the transaction, the insider now owns 17,178,585 shares […]
UBS Group AG raised its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) by 177.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 289,727 shares of the company’s stock after buying an additional 185,199 shares during the quarter. UBS Group […]
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) gapped down prior to trading on Thursday . The stock had previously closed at $26.10, but opened at $25.31. Vir Biotechnology shares last traded at $25.99, with a volume of 43,800 shares trading hands. Analyst Ratings Changes A number of research analysts recently weighed in on the company. […]